anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The development of a potentially life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including fluoxetine treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms.

The concomitant use of fluoxetine with MAOIs intended to treat depression is contraindicated [see Contraindications (4) and Drug Interactions (7.1)]. 

If concomitant treatment of fluoxetine with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Drug Interactions (7.4)].

The concomitant use of fluoxetine with serotonin precursors (such as tryptophan) is not recommended [see Drug Interactions (7.3)]. 

Treatment with fluoxetine and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above reactions occur, and supportive symptomatic treatment should be initiated.
Once a moderate subject has been recruited, a healthy control subject should be recruited (matched to the moderate subject on gender, ethnicity, body mass index +/-15%, age +/-5 years). In total there will be 9 matched healthy volunteers 1 for each subject with moderate hepatic impairment.
Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
BACKGROUND & AIMS: Dysregulated cholesterol metabolism is the major factor responsible for cholesterol gallstones (CGS). Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in cholesterol homeostasis and its inhibitors secure approval for treating various cholesterol metabolic disorders such as hypercholesterolemia and cardiovascular diseases, but its role in CGS remains unclear. Our study aims to clarify mechanisms by which PCSK9 promotes CGS formation and explore the application of the PCSK9 inhibitor, alirocumab, in preventing and treating CGS.
APPROACH & RESULTS: The expressions of PCSK9 were notably increased in CGS patients' serum, bile, and liver tissues compared to those without gallstones. Moreover, among CGS patients, hepatic PCSK9 was positively correlated with hepatic cholesterol and negatively correlated with hepatic bile acids (BAs), suggesting PCSK9 was involved in disrupted hepatic cholesterol metabolism related to CGS. Mechanistically, in vitro experiments demonstrated that inhibition of PCSK9 enhanced nuclear expression of PPARα by diminishing its lysosomal degradation and subsequently activated CYP7A1 transcription. Finally, inhibition of PCSK9 prevented CGS formation and dissolved the existing stones in CGS mice by elevating the conversion of cholesterol into BAs through PPARα-mediated CYP7A1 activation. Additionally, serum PCSK9 level may function as a prognostic signature to evaluate the therapeutic efficacy of PCSK9 inhibitors.
CONCLUSIONS: Inhibition of PCSK9 exerts preventive and therapeutic effects on CGS by activating PPARα-mediated CYP7A1 expression and facilitating the conversion of cholesterol into BAs, which highlights the potential of PCSK9 inhibition as a promising candidate for preventing and treating CGS in clinical applications.
IMPACT AND IMPLICATIONS: PCSK9 plays a pivotal role in cholesterol metabolism and its inhibitors are approved for clinical use in cardiovascular diseases. Our study observes inhibition of PCSK9 prevents and dissolves CGS by activating PPARα-mediated CYP7A1 expression and facilitating the conversion of cholesterol into BAs. Mechanistically, PCSK9 inhibition enhanced the nuclear expression of PPARα by diminishing its lysosomal degradation and subsequently activated CYP7A1 transcription. Our study sheds light on the new function and mechanism of PCSK9 in CGS, providing a novel preventive and therapeutic target with potential clinical applications.
CANVAS is a recently characterized repeat expansion disease, most commonly caused by homozygous expansions of an intronic (A2G3)n repeat in the RFC1 gene. There are a multitude of repeat motifs found in the human population at this locus, some of which are pathogenic and others benign. In this study, we conducted structure-functional analyses of the pathogenic (A2G3)n and nonpathogenic (A4G)n repeats. We found that the pathogenic, but not the nonpathogenic, repeat presents a potent, orientation-dependent impediment to DNA polymerization in vitro. The pattern of the polymerization blockage is consistent with triplex or quadruplex formation in the presence of magnesium or potassium ions, respectively. Chemical probing of both repeats in vitro reveals triplex H-DNA formation by only the pathogenic repeat. Consistently, bioinformatic analysis of S1-END-seq data from human cell lines shows preferential H-DNA formation genome-wide by (A2G3)n motifs over (A4G)n motifs. Finally, the pathogenic, but not the nonpathogenic, repeat stalls replication fork progression in yeast and human cells. We hypothesize that the CANVAS-causing (A2G3)n repeat represents a challenge to genome stability by folding into alternative DNA structures that stall DNA replication.
Lipedema is a syndrome of painful fatty enlargement of the buttocks, hips and thighs primarily in women which cannot be lost by diet, exercise or bariatric surgery. Arms are affected in 80% of women with lipedema to varying degrees. The etiology of lipedema is not known and there are no evidence-based treatments that work for a majority of individuals except for excision of the subcutaneous adipose tissue (SAT) by liposuction which has risks. Millions of women are affected with lipedema yet they are grossly under-diagnosed, have mobility issues and can develop lymphedema. The goal of this project is to better understand the etiology of lipedema SAT, find out how it is different from non-lipedema SAT, to improve our ability to identify the abnormal SAT and determine the response of the tissue to therapeutics by imaging and biomarkers. People with diffuse Dercum's disease (DD) appear to have lipedema plus a tissue inflammation that causes illness and pain. People with SAT disorders that have similarities to lipedema will also be included in this protocol. More research is needed to determine how these fatty disorders are similar and different from each other and from obesity so they can be distinguished clinically and by laboratory testing and imaging. Since these painful fatty disorders are associated with SAT growth, research focused on these disorders may provide unique insight into mechanisms of obesity.
The imagery group, will sit on the leg press and image completing 3 sets of leg press. The imagery group will be asked to fill out the Movement Imagery Questionnaire -revised as this gives us a measure of imagery ability. The imagery group will be given an imagery script prior to imaging. Weekly manipulation checks will be completed to ensure that participants are imagining what they are supposed to.
A controlled release formulation for use with a variety of drugs or hormones are formed in microspherical form. The drug or hormone, e.g. bovine somatropine, is suspended in a polymer matrix. The polymer matrix is formed from at least two highly water soluble biodegradable polymers, selected for example from starch, crosslinked starch, ficoll, polysucrose, polyvinyl alcohol, gelatine, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-ethyl cellulose, hydroxypropyl-methyl cellulose, sodium carboxymethyl cellulose, cellulose acetate, sodium alginate, polymaleic anhydride esters, polyortho esters, polyethyleneimine, polyethylene glycol, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene oxide,poly(1,3 bis(p-carboxyphenoxy) propane-co-sebacic anhydride, N,N-diethylaminoacetate, block copolymers of polyoxyethylene and polyoxypropylene. The microspheres are coated with a (d,1 lactide-glycolide) copolymer. The coating makes the microspheres more resistant to enzymatic degradation.
INTRODUCTION: Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ventricular ejection fraction (LVEF) in sinus rhythm. It is unclear why some patients develop AIC.
HYPOTHESIS: Patients with AIC have a subtle cardiomyopathic process that precedes their AF-mediated LVEF reduction. Detailed assessment of cardiac function after successful catheter ablation will reveal this.
OBJECTIVE: To evaluate the utility of measures to identify cardiomyopathic features that persist after LVEF normalisation in AIC.
METHODS: Patients with rate-controlled persistent AF and LVEF<50% undergoing catheter ablation (CA) were prospectively evaluated using echocardiography, cardio-pulmonary exercise testing and serum N-terminal pro b-type natriuretic peptide (NT-proBNP) at baseline and 6 months after CA. Participants with AIC, (LVEF recovery (≥50%) and no other cause for cardiac dysfunction) were evaluated using left ventricular (LV) longitudinal strain and left atrial (LA) reservoir strain (LARS). Changes in peak oxygen consumption and the minute ventilation/carbon dioxide production slope were measured as markers of functional capacity and ventilatory inefficiency. A control group of patients with persistent AF with preserved LVEF were also enrolled.
RESULTS: 34/41 (82.9%) participants recovered LVEF in sinus rhythm; defined as AIC. NT-proBNP levels were elevated in 18 (52.9%), and 16 reported ongoing heart failure (HF) symptoms. 10 (29.4%) had no improvement in functional capacity, and seven (20.6%) showed persistent ventilatory inefficiency. 20 (58.8%) had impaired global LV longitudinal strain with a relative apical sparing pattern. Nine (26.5%) had impaired LARS. There was an overlap of these abnormalities. 32 (94.1%) demonstrated at least one, 17 (50.0%) having no cardiovascular risk factors. Patients with preserved LVEF during persistent AF had similar demographics but a lower burden of short R-R intervals (<660 ms) on Holter monitoring.
DISCUSSION: Abnormal structural, metabolic and HF biomarkers are seen in patients with AIC in sinus rhythm. These features may represent a precedent subtle cardiomyopathic process predisposing them to left ventricular systolic dysfunction in AF.
TRIAL REGISTRATION NUMBER: NCT04987723.
FIELD: food industry. ^ SUBSTANCE: invention refers to confectionary industry. Chewing confectionary composition contains from 0.1 to 3 % of weight of enzyme, solid material of base, sweetener not provoking caries, substance stabilising enzymes and water below 5% of weight. Enzyme is chosen from proteases extracted from fruit products and is introduced into solid material of composition base at temperature 80C, also enzyme activity of proteases is maintained in the composition at least for 4 weeks at 23C. ^ EFFECT: introduction of enzyme into composition facilitates destructing of dental deposit, prevents its formation and adhesion on teeth surface at product consumption. ^ 13 cl, 7 tbl, 1 ex
PURPOSE:To obtain a resin, etc., containing uniformly dispersed antibacterial powder and having high antibacterial property, by mixing antibacterial powder such as antibacterial zeolite with a dispersion medium such as thermoplastic resin under reduced pressure at a temperature to keep the dispersion medium in liquid state. CONSTITUTION:The title dispersion is produced by mixing antibacterial powder (e.g. antibaqterial zeolite or antibacterial amorphous aluminosilicate) with a dispersion medium (e.g. thermoplastic resin, polyols or higher fatty acids) under reduced pressure (<=470Torr, preferably <=250Torr) at a temperature to keep the dispersion medium in liquid state. The antibacterial zeolite can be produced by substituting the total or a part of ion-exchangeable ion in zeolite with antibacterial metal ion (e.g. ion of silver, copper or zinc) and ammonium ion. The antibacterial powder can be dispersed in the resin, etc., preventing the agglomeration of the powder on the surface and, accordingly, a resin, etc., having high antibacterial property can be produced.
Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at \> 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
Signs of overdose may include confusion, drowsiness, continuing headache, problems with passing urine and rapid weight gain due to fluid retention. (See WARNINGS.) In case of overdose, the dose should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. There is no known specific antidote for desmopressin acetate. The patient should be observed and treated with appropriate symptomatic therapy.

An oral LD50 has not been established. Oral doses up to 0.2 mg/kg/day have been administered to dogs and rats for 6 months without any significant drug-related toxicities reported. An intravenous dose of 2 mg/kg in mice demonstrated no effect.
BACKGROUND: Tubal mesosalpinx cysts are paratubal cysts, that account for approximately 10% of adnexal masses, and the presence of these cysts combined with adnexal torsion is a rare acute abdominal condition, with few cases reported in the literature. We reported two cases of adolescent tubal mesosalpinx cysts combined with adnexal torsion and reviewed the literature to help improve the diagnosis of the disease.
CASE REPORTS: The first patient was an 11-year-old girl with left lower abdominal pain for 5 days and fever with nausea and vomiting for 3 days, who was found to have a cystic pelvic mass on preoperative imaging and was diagnosed intraoperatively and postoperatively on pathology as having a left tubal mesosalpinx cyst combined with adnexal torsion. The second patient was a 13-year-old girl with right lower abdominal pain for 16 h and a palpable mass in the lower and middle abdomen on examination, which was hard and tender to palpate. Preoperative imaging revealed a large cystic mass in the right adnexal region, and intraoperative and postoperative pathology revealed a right tubal mesosalpinx cyst combined with adnexal torsion.
CONCLUSIONS: Tubal mesosalpinx cysts combined with adnexal torsion are rare causes of acute lower abdominal pain. Early diagnosis and timely surgery are necessary to ensure ovarian and tubal function. Accurate preoperative imaging diagnosis is challenging, and MRI is a beneficial supplement to ultrasound and CT examinations, providing more objective imaging information and reducing the incidence of adverse outcomes.
<P>PROBLEM TO BE SOLVED: To provide a method for controlling the expression of SMN gene.  <P>SOLUTION: A nucleic acid for a splicing control factor or a variant thereof comprising a specific base sequence is provided. A nucleic acid-introducing carrier containing the nucleic acid is provided. The method for controlling the expression of SMN gene using the nucleic acid is provided. A pharmaceutical composition containing the nucleic acid or the carrier as active ingredient is provided. A method for retrieving a splicing-enhancing substance for SMN gene's exon 7 is also provided, comprising the following steps: in the presence/absence of a specimen, a cell is maintained which contains an exon trap vector construct operably bound with a nucleic acid construct comprising SMN2 gene's intron 6, SMN2 gene's exon 7 and SMN2 gene's intron 7 containing a nucleic acid for a splicing control element comprising a specific base sequence, and the amount of a transcription product corresponding to the SMN2 gene's exon 7 in the cell obtained in the presence of the specimen and the amount of a transcription product corresponding to the SMN2 gene's exon 7 in the cell obtained in the absence of the specimen are measured.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Disclosed is a method for reducing an immune response to a parenterally administered non-autologous antigen in an individual who is immunologically responsive thereto by mucosally administering to the individual an amount of the antigen effective to reduce any immune response to parenteral administration of said antigen. The antigen can be a polypeptide such as a hormone, like insulin, which supplements a metabolic deficiency in the recipient of a polypeptide intended to serve the same function. The polypeptide can also be one which supplements a deficiency in the production of a physiologically important polypeptide, such as a hematologic regulatory factor. The hematologic regulatory factor can enhance or inhibit thrombogenesis or platelet deposition. Also, the antigen can be a tissue or cell preparation, such as of allogeneic or xenogeneic tissue or cells. The method for reducing an immune response is preferably one which induces tolerance to parenteral administration of the antigen, such as by inducing or elevating a suppressor T cell response to the mucosally administered antigen.
PURPOSE:To attain the high speed retrieval of a medical picture by storing altogether each medical diagnostic picture in each picture device by which it is picked-up, and displaying the picture corresponding to the specification the medical diagnostic picture device for a patient. CONSTITUTION:Files managed by an operating system are present on a recording medium 1, and CT picture data are stored in files 2A-2C. That is, a file 2 is a directory file in which the names of the files 2A-2C are stored, and the stored file name of the CT picture is judged by checking the file 2. In the same way, MR picture data are stored in files 3A and 3B, and a file 3 is the directory file in which the names of the files 3A and 3B are stored. Moreover, DR picture data are stored in a file 4A, and the name of the file 4A is stored in a file 4. Therefore, the medical diagnostic picture is read out of a storage device and displayed, corresponding to the specification of the photographing device.
The present invention relates to a stabilized pharmaceutical tablet comprising an amount of from 0.1 to 10% by weight of tibolone provided with a coating, such as a film coating, a sugar coating, a sugar film coating or a “wrap” coating. The invention further relates to the use of a coating for stabilizing a pharmaceutical tablet comprising tibolone. Preferably, the coating is a sugar coating or a sugar film coating. Preferably, the sugar comprises sucrose. These tablets were shown to have a lower amount of OM38, i.e. an isomerization degradation product of tibolone, after storage as compared to uncoated tibolone tablets.
Arm A: 18-26 years old. Random, double blind, Gardasil®9 positive control and placebo control was conducted in 1200 healthy women. Middle dose SCT1000: hight dose SCT1000: placebo: positive control =1:1:1:1.Arm B: 27-45 years old. Random, double blind, Gardasil® positive control and placebo control was conducted in 600 healthy women. Middle dose SCT1000: hight dose SCT1000: placebo: positive control =1:1:1:1.Two arms can be recruited at the same time. If the DSMB assessment shows that the adverse events of a certain dose group meet the criteria of suspension / termination, the dose group will be suspended / terminated, and the study of other dose groups will continue.
Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress the complex type 2 (T2) inflammatory cascade. Biologics targeting more upstream molecules in the pathophysiological pathway of asthma could treat asthma more effectively. Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). It is the first marketed biologic against an epithelial cell-derived cytokine, preventing binding of TSLP to its receptor and reducing the immune stimuli that TSLP can trigger in different asthma endotypes. Tezepelumab reduces downstream biomarkers of inflammation, such as blood and airway eosinophils, FeNO, IgE, IL-5, and IL-13. Tezepelumab provides a clinical benefit in severe asthma, reducing the annualized asthma exacerbation rate in patients with either high or low levels of biomarkers of T2 inflammation, although the effect is greater among those with high levels. The drug has been shown to improve asthma control, quality of life, and lung function and reduce airway hyperresponsiveness. Therefore, tezepelumab can be used across the spectrum of patients with severe uncontrolled asthma, especially in T2-high patients. This review includes a positioning statement by the authors, all of whom are members of the SEAIC Asthma Committee.
Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
Participants will be randomized into two groups. The Pulmonary Rehabilitation group will undergo exercise under a supervised setting for a total duration of 12 weeks. Patients will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session. Exercises will be supervised by physiotherapists or exercise physiologists. Compliance and performance will be monitored by the trainer. They will receive a pedometer for home use. The Home based program group will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Patients will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
The invention relates to a daily washing and cleaning article, in particular to a mint handmade soap and a preparation method thereof. The handmade soap comprises the following raw materials: water, plant glycerin, mint essential oil, spearmint essential oil, ginkgo extracted liquid, and guarana extracted liquid. Mint essential oil has the efficacy of relieving inflammation and itching, contracting capillaries, softening skin, eliminating acne, and conditioning oily skin. Spearmint essential oil can assist conditioning oily skin to a stable and normal skin condition. Flavonoids mainly coming from the ginkgo extracted liquid have strong and powerful antioxidant effect, and can inhibit allergy symptoms. Therefore, the handmade soap provided by the invention has the characteristics of long preservation time and simple making method, and is a safe and effective skin cleaning product.